Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
2267 On Other Exchanges
Symbol
Exchange
2267 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

yakult honsha co ltd (2267) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for YAKULT HONSHA CO LTD (2267)

Related News

No related news articles were found.

yakult honsha co ltd (2267) Related Businessweek News

View More BusinessWeek News

yakult honsha co ltd (2267) Details

Yakult Honsha Co., Ltd., a probiotics company, primarily manufactures and sells food and beverage products. It operates through Food and Beverages (Japan), Food and Beverages (The Americas), Food and Beverages (Asia and Oceania), Food and Beverages (Europe), Pharmaceuticals, and Others. The company offers food and beverages products comprising fermented milk drinks, juices, noodles, etc. through its home delivery and retail store channels. It also provides pharmaceutical products, including Elplat, a cancer chemotherapeutic agent for the treatment of colorectal cancer; Levofolinate Yakult, an activated folic acid drug; Gemcitabine Yakult, an antineoplastic antimetabolite; recombinant DNA G-CSF chemotherapy preparation Neu-up; Imatinib yakult, a generic antineoplastic drug; and Campto, an active pharmaceutical ingredient. The company is also developing Elplat for gastric cancer; PR610, a hypoxia activated pro drug; Perifosine, a PI3K/Akt inhibitor; Resminostat, an oral HDAC inhibitor; LIV-2008, which are humanized monoclonal anticancer antibodies; antibody biosimilars; and Zoledronic acid intravenous drip, a generic drug for bone lesions. In addition, it offers cosmetics and skin care products under the Parabio, Revecy, and Revecy White brand names; and BECYCLE Lift Repair Essence, which adds firmness and resilience to the skin, as well as operates and manages the Tokyo Yakult Swallows, a professional baseball team. The company was founded in 1935 and is headquartered in Tokyo, Japan.

20,492 Employees
Last Reported Date: 06/26/14
Founded in 1935

yakult honsha co ltd (2267) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: ¥150.0M
Compensation as of Fiscal Year 2014.

yakult honsha co ltd (2267) Key Developments

Yakult Honsha Co. Ltd. Reports Consolidated and Parent Earnings Results for the Third Quarter Ended Dec. 31, 2014

Yakult Honsha Co. Ltd. reported consolidated and parent earnings results for the third quarter ended December 31, 2014. For the quarter, the group reported net sales of ¥279,907 million against ¥264,156 million for the same period of last year. Operating income was ¥29,488 million against ¥25,449 million for the same period of last year. Income before income taxes and minority interests was ¥36,427 million against ¥31,824 million for the same period of last year. Net income was ¥21,553 million against ¥18,545 million for the same period of last year. For the quarter, the parent company reported net sales of ¥136,656 million against ¥136,056 million for the same period of last year. Operating income was ¥4,502 million against ¥1,863 million for the same period of last year. Net income was ¥7,344 million against ¥5,284 million for the same period of last year.

Yakult Honsha Co. Ltd., Q3 2015 Earnings Call, Jan 30, 2015

Yakult Honsha Co. Ltd., Q3 2015 Earnings Call, Jan 30, 2015

Yakult Honsha Co. Ltd. to Report Q3, 2015 Results on Jan 30, 2015

Yakult Honsha Co. Ltd. announced that they will report Q3, 2015 results on Jan 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
2267:JP ¥7,810.00 JPY -10.00

2267 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott India Ltd 3,874 INR +23.90
BioGaia AB kr225.50 SEK 0.00
Biostime International Holdings Ltd $37.25 HKD -0.65
Mead Johnson Nutrition Co $97.94 USD +1.53
View Industry Companies
 

Industry Analysis

2267

Industry Average

Valuation 2267 Industry Range
Price/Earnings 50.6x
Price/Sales 3.5x
Price/Book 4.3x
Price/Cash Flow 53.9x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact YAKULT HONSHA CO LTD, please visit www.yakult.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.